Sign in
Taking people in United StatesNo phase

Mucopolysaccharidosis VII Disease Monitoring Program

Key facts

Who runs it
Ultragenyx Pharmaceutical Inc
Where
Ann Arbor, Chicago, New York, Orange, Salt Lake City, Seattle, and Washington D.C., United StatesSee the 7 sitesAlso in 7 other countries, 7 sites
Trial code
Status
Recruiting
People taking part
50 people, planned
Started
29 Jan 2018
Expected to end
Apr 2032
Type of study
Observational, 2 groups
Record updated
27 August 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Diagnosis of MPS VII based on laboratory diagnosis, including either enzymatic or mutation analysis
  • Willing and able to provide written informed consent or, in the case of patients under the age of 18 (or below adult ages as defined by local laws and regulations) or patients >18 years of age who have cognitive deficiencies, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the DMP has been explained, and prior to any research-related procedures
  • Willing to comply with DMP visit schedule

Who cannot take part

  • Concurrent participation in other pharmaceutical company-sponsored interventional clinical trial unless approved by Ultragenyx

This trial is currently available in United States.

Also in 7 other countries, 7 sites

  • University of MichiganAnn Arbor, United StatesTaking people
  • Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesTaking people
  • New York University Langone Medical CenterNew York, United StatesNo longer taking part
  • Children's Hospital of Orange CountyOrange, United StatesTaking people
  • University of Utah Medical CenterSalt Lake City, United StatesTaking people
  • Seattle Children's HospitalSeattle, United StatesTaking people
  • Children's National Health SystemWashington D.C., United StatesTaking people

About the trial

What the trial wants to find out

The objectives of this study are to characterize MPS VII disease presentation and progression and assess long-term effectiveness and safety, including hypersensitivity reactions and immunogenicity of vestronidase alfa.

The 2 groups in the trial

  • Patients with MPS VII receiving vestronidase-alfa

    via prescription, or early access/ compassionate use program

  • Patients with MPS VII not receiving vestronidase-alfa

    no treatment or treatment other than vestronidase alfa

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Mucopolysaccharidosis VII Disease Monitoring Program (MPS VII DMP)
Record updated
27 August 2026